AlphAIAlphAI — Financial news for AI agents
gurufocus.comSEP 133 min read$JNJ

Johnson & Johnson's Orthopedic Unit Sale Talks with Apollo Globa

Apollo Global Management is in talks to acquire Johnson & Johnson's (JNJ) DePuy Synthes orthopedic division for around $20 billion. JNJ, trading at $265.58, is seen as 37.4% overvalued with a GF Value of $193.26. The company has a strong dividend yield of 1.99% and a GF Score of 83, indicating robust financial health. Insiders have sold $67.8 million in shares recently.

Original reporting
gurufocus.com
Published Sep 13, 2026, 7:03 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 13, 2026, 7:31 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefMergers & acquisitions
Primary signal
$JNJ
Bearish
high confidence
Mentioned
$JNJ
Relevance
9/10
AlphAI data visualization · based on gurufocus.com
Decision brief

The 30-second read

$JNJBearishHigh
01

Why it matters

The deal could reshape JNJ’s revenue profile and affect med‑tech valuations; investors may react with short‑term weakness but could benefit from cash proceeds later.

02

Market read

A large‑scale M&A talk involving a $20 billion orthopedic business could shift sector dynamics and influence JNJ’s valuation.

03

What to watch

Potential tax benefits, strategic partnership opportunities for DePuy Synthes under new ownership, and possible use of proceeds for share buybacks.

Relevance 9/10Novelty 9/10Timing: today (Sep 13)

Background

Johnson & Johnson’s orthopedic unit DePuy Synthes is reported to be in sale talks with Apollo Global Management for about $20 billion, amid broader portfolio streamlining.

Company-level read

Ticker impact

$JNJBearishHigh confidence
Context

Apollo Global Management is negotiating to acquire Johnson & Johnson's DePuy Synthes orthopedic division for approximately $20 billion.

Expected impact

Downward pressure on JNJ stock, possible 2‑4% dip as investors reassess earnings outlook.

Evidence & confidence

A $20 B sale of a core orthopedic business is material; the market will price in reduced revenue and integration risk.

Market effects

Sector

Signals consolidation in the medical‑device sector, prompting reassessment of other med‑tech peers.

Regional

May weigh on US healthcare and pharma indices as JNJ’s core business mix changes.

Global

Highlights growing interest from private‑equity firms in large‑cap health‑care assets worldwide.

Counterpoint

What could challenge this read

The divestiture could unlock cash, reduce debt, and sharpen JNJ’s focus on higher‑growth pharma, potentially supporting the stock long term.

Key entities

  • Company
    Johnson & Johnson

    US healthcare conglomerate considering sale of its DePuy Synthes division.

  • Private‑equity firm
    Apollo Global Management

    Potential acquirer of DePuy Synthes.

  • Business unit
    DePuy Synthes

    JNJ’s orthopedic division targeted for sale.

Read at source← All news

Also covered by

5 outlets

Related articles

OCT 3
$MRKHigh

Big Pharma Bets $2.2 Billion on Previously 'Undruggable' KRAS G12D; Race for Pancreatic Cancer Targeted Therapies Heats Up

Merck and Bayer have invested billions in KRAS G12D inhibitors for pancreatic cancer, with Merck paying $2.13B for a preclinical candidate. Johnson & Johnson and Eli Lilly are also developing therapies, while Revolution Medicines' RMC-6236 received FDA approval. Competition is intense, with first-to-market advantages and high commercial potential.

finance.biggo.com3 min
OCT 2
$JNJMed

Johnson & Johnson Announces New ICOTYDE Icotrokinra Data In Difficult-To-Treat Plaque Psoriasis With Proven Durability Through 2 Years

Johnson & Johnson reported two-year data from the ICONIC-TOTAL study, showing sustained skin clearance in patients with high-impact plaque psoriasis treated with ICOTYDE. At Week 112, 70% of patients achieved clear or almost clear skin, with high rates of site-specific clearance. Safety findings were consistent with ICOTYDE's established profile. The drug is approved in the U.S., Europe, Japan, and China for plaque psoriasis and is being studied for other conditions.

marketscreener.com2 min
OCT 2
$JNJMedAI 8/10

Johnson & Johnson reports two-year ICOTYDE data showing sustained clearance in high-impact psoriasis

Johnson & Johnson reported two-year data for ICOTYDE, showing sustained skin clearance in high-impact psoriasis. Clear or almost clear skin increased from 57% to 70% by Week 112. Complete clearance rates were 60% for scalp, 89% for genital, and 63% for hands/feet. Nail psoriasis improved, with mNAPSI scores rising from 33% to 71%. Safety findings were consistent with no new signals. ICOTYDE is approved for plaque psoriasis and is being studied for other conditions.

marketscreener.com1 min